Janssen has announced that the US Biomedical Advanced Research and Development Authority (BARDA) will be assisting the development of its new Ebola vaccine regimen.
The authority, which is part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, will provide $44.7 million (33.57 million pounds) over five years to support the development and potential licensing of the vaccine candidate.
“Janssen is partnering with the US Biomedical Advanced Research and Development Authority to advance the development of its Ebola vaccine regimen.“
This novel regimen involves an initial dose that primes the immune system to develop disease-specific immune responses, followed by a booster dose that strengthens and optimises the duration of the response.
Janssen has been working on the development of an Ebola vaccine for several years, and accelerated its work during the 2014-16 Ebola outbreak in West Africa with an extra commitment of $200 million.
Dr Johan Van Hoof, global head of infectious diseases and vaccines at Janssen, said: "Never before has Johnson and Johnson mobilised resources so rapidly to accelerate a vaccine candidate - supporting the initiation of multiple clinical trials across three continents in just one year."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical